MSH2 and mismatch repair cancer syndrome 1: Our results begin to identify additional vulnerabilities in MSI-H or MSH2/MLH1-mutant CRCs that may be considered in designing therapeutic options for patients with advanced CRC, and the insights may apply to other tumors with mismatch repair deficiency.